FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract Cancer
FDA批准摘要:度伐利尤单抗和帕博利珠单抗,用于治疗胆道癌的免疫检查点抑制剂
期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-24-0517
Casak, Sandra J; Kumar, Vaibhav; Song, Chi; Yuan, Mengdie; Amatya, Anup K; Cheng, Joyce; Mishra-Kalyani, Pallavi S; Tang, Shenghui; Lemery, Steven J; Auth, Doris; Davis, Gina; Kluetz, Paul G; Pazdur, Richard; Fashoyin-Aje, Lola A
Checkpoint
肿瘤
肿瘤免疫
胆管癌
免疫/内分泌